CELC - Celcuity Inc.
IEX Last Trade
10.765
-0.025 -0.232%
Share volume: 13,444
Last Updated: Mon 13 Jan 2025 08:30:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.44%
PREVIOUS CLOSE
CHG
CHG%
$10.79
-0.02
-0.23%
Fundamental analysis
8%
Profitability
8%
Dept financing
8%
Liquidity
47%
Performance
0%
Performance
5 Days
-6.14%
1 Month
-4.79%
3 Months
-21.37%
6 Months
-36.56%
1 Year
-17.79%
2 Year
2.32%
Key data
Stock price
$10.76
DAY RANGE
$10.44 - $10.95
52 WEEK RANGE
$12.28 - $22.19
52 WEEK CHANGE
-$17.79
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Brian F. Sullivan
Region: US
Website: celcuity.com
Employees: 40
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: celcuity.com
Employees: 40
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.
Recent news